Which has higher valuation & earnings, WRBY or SIBN?

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Warby Parker $890.57M 3.36 $1.64M $0.02 1,395.80 SiBone $200.93M 3.81 -$18.90M -$0.39 N/A

Is WRBY or SIBN more profitable?

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets Warby Parker 0.15% 2.30% 1.18% SiBone -8.10% -9.56% -7.06%

Does the media refer more to WRBY or SIBN?

In the previous week, SiBone had 2 more articles in the media than Warby Parker. MarketBeat recorded 5 mentions for SiBone and 3 mentions for Warby Parker. SiBone's average media sentiment score of 0.58 beat Warby Parker's score of 0.41 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ESTA or SIBN more profitable?

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% SiBone -8.10% -9.56% -7.06%

Does the media refer more to ESTA or SIBN?

In the previous week, SiBone had 3 more articles in the media than Establishment Labs. MarketBeat recorded 5 mentions for SiBone and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.14 beat SiBone's score of 0.58 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TMDX or SIBN?

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $635.89M 4.10 $190.29M $4.40 17.13 SiBone $200.93M 3.81 -$18.90M -$0.39 N/A

Does the media refer more to TMDX or SIBN?

In the previous week, SiBone had 2 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for SiBone and 3 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.69 beat SiBone's score of 0.58 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, AXGN or SIBN?

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.14 -$15.70M -$0.64 N/A SiBone $200.93M 3.81 -$18.90M -$0.39 N/A

Is AXGN or SIBN more profitable?

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% SiBone -8.10% -9.56% -7.06%

Does the media refer more to AXGN or SIBN?

In the previous week, AxoGen had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for AxoGen and 5 mentions for SiBone. AxoGen's average media sentiment score of 0.91 beat SiBone's score of 0.58 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LMAT or SIBN?

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 9.14 $57.73M $2.71 36.82 SiBone $200.93M 3.81 -$18.90M -$0.39 N/A

Does the media favor LMAT or SIBN?

In the previous week, LeMaitre Vascular had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for LeMaitre Vascular and 5 mentions for SiBone. SiBone's average media sentiment score of 0.58 beat LeMaitre Vascular's score of 0.14 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

SiBone (SIBN) Competitors

$17.25 +0.34 (+2.01%)

Closing price 07/15/2026 04:00 PM Eastern

Extended Trading

$17.24 -0.01 (-0.06%)

As of 07/15/2026 04:10 PM Eastern

Compare

SIBN vs. WRBY, ESTA, TMDX, AXGN, and LMAT

Should you buy SiBone stock or one of its competitors? MarketBeat compares SiBone with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SiBone include Warby Parker (WRBY), Establishment Labs (ESTA), TransMedics Group (TMDX), AxoGen (AXGN), and LeMaitre Vascular (LMAT). These companies are all part of the "medical equipment" industry.

How does SiBone compare to Warby Parker?

Warby Parker (NYSE:WRBY) and SiBone (NASDAQ:SIBN) are both medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, SiBone had 2 more articles in the media than Warby Parker. MarketBeat recorded 5 mentions for SiBone and 3 mentions for Warby Parker. SiBone's average media sentiment score of 0.58 beat Warby Parker's score of 0.41 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Warby Parker	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Warby Parker has a net margin of 0.15% compared to SiBone's net margin of -8.10%. Warby Parker's return on equity of 2.30% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Warby Parker	0.15%	2.30%	1.18%
SiBone	-8.10%	-9.56%	-7.06%

Warby Parker currently has a consensus target price of $29.82, indicating a potential upside of 6.81%. SiBone has a consensus target price of $23.00, indicating a potential upside of 33.33%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

93.2% of Warby Parker shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 16.8% of Warby Parker shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Warby Parker has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Warby Parker	$890.57M	3.36	$1.64M	$0.02	1,395.80
SiBone	$200.93M	3.81	-$18.90M	-$0.39	N/A

Warby Parker has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

Warby Parker beats SiBone on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 4.0% of SiBone shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Establishment Labs presently has a consensus target price of $90.43, suggesting a potential downside of 0.21%. SiBone has a consensus target price of $23.00, suggesting a potential upside of 33.33%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$229.58M	11.62	-$51.06M	-$1.49	N/A
SiBone	$200.93M	3.81	-$18.90M	-$0.39	N/A

Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

SiBone has a net margin of -8.10% compared to Establishment Labs' net margin of -19.05%. SiBone's return on equity of -9.56% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, SiBone had 3 more articles in the media than Establishment Labs. MarketBeat recorded 5 mentions for SiBone and 2 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.14 beat SiBone's score of 0.58 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

SiBone beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does SiBone compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TransMedics Group has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$635.89M	4.10	$190.29M	$4.40	17.13
SiBone	$200.93M	3.81	-$18.90M	-$0.39	N/A

TransMedics Group currently has a consensus price target of $134.50, suggesting a potential upside of 78.43%. SiBone has a consensus price target of $23.00, suggesting a potential upside of 33.33%. Given TransMedics Group's higher possible upside, equities research analysts plainly believe TransMedics Group is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

TransMedics Group has a net margin of 27.04% compared to SiBone's net margin of -8.10%. TransMedics Group's return on equity of 22.38% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
SiBone	-8.10%	-9.56%	-7.06%

TransMedics Group has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

In the previous week, SiBone had 2 more articles in the media than TransMedics Group. MarketBeat recorded 5 mentions for SiBone and 3 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.69 beat SiBone's score of 0.58 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TransMedics Group beats SiBone on 13 of the 15 factors compared between the two stocks.

How does SiBone compare to AxoGen?

AxoGen (NASDAQ:AXGN) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

AxoGen currently has a consensus price target of $46.50, indicating a potential upside of 20.09%. SiBone has a consensus price target of $23.00, indicating a potential upside of 33.33%. Given SiBone's higher probable upside, analysts clearly believe SiBone is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

AxoGen has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

AxoGen has higher revenue and earnings than SiBone. AxoGen is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.14	-$15.70M	-$0.64	N/A
SiBone	$200.93M	3.81	-$18.90M	-$0.39	N/A

SiBone has a net margin of -8.10% compared to AxoGen's net margin of -13.21%. SiBone's return on equity of -9.56% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
SiBone	-8.10%	-9.56%	-7.06%

In the previous week, AxoGen had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for AxoGen and 5 mentions for SiBone. AxoGen's average media sentiment score of 0.91 beat SiBone's score of 0.58 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AxoGen beats SiBone on 9 of the 16 factors compared between the two stocks.

How does SiBone compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and SiBone (NASDAQ:SIBN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

LeMaitre Vascular has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

LeMaitre Vascular has a net margin of 24.35% compared to SiBone's net margin of -8.10%. LeMaitre Vascular's return on equity of 15.36% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
SiBone	-8.10%	-9.56%	-7.06%

LeMaitre Vascular has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.14	$57.73M	$2.71	36.82
SiBone	$200.93M	3.81	-$18.90M	-$0.39	N/A

LeMaitre Vascular currently has a consensus price target of $112.60, indicating a potential upside of 12.84%. SiBone has a consensus price target of $23.00, indicating a potential upside of 33.33%. Given SiBone's stronger consensus rating and higher possible upside, analysts clearly believe SiBone is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, LeMaitre Vascular had 1 more articles in the media than SiBone. MarketBeat recorded 6 mentions for LeMaitre Vascular and 5 mentions for SiBone. SiBone's average media sentiment score of 0.58 beat LeMaitre Vascular's score of 0.14 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LeMaitre Vascular beats SiBone on 10 of the 16 factors compared between the two stocks.

Get SiBone News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SIBN vs. The Competition

Export

Metric	SiBone	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$749.95M	$7.43B	$6.78B	$12.56B
Dividend Yield	N/A	1.34%	2.68%	9.45%
P/E Ratio	-44.23	50.74	27.08	24.35
Price / Sales	3.81	79.06	487.23	76.01
Price / Cash	N/A	26.20	48.63	60.00
Price / Book	4.22	7.21	10.82	6.31
Net Income	-$18.90M	$162.30M	$3.59B	$331.55M
7 Day Performance	-0.98%	-0.75%	-1.80%	-0.71%
1 Month Performance	11.94%	0.12%	3.71%	0.16%
1 Year Performance	0.88%	8.24%	27.41%	19.66%

SiBone Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SIBN SiBone	2.7155 of 5 stars	$17.25 +2.0%	$23.00 +33.3%	+2.0%	$749.95M	$200.93M	N/A	350	News Coverage
WRBY Warby Parker	2.5407 of 5 stars	$28.38 -2.9%	$29.82 +5.1%	+21.8%	$3.05B	$871.91M	1,424.86	4,036
ESTA Establishment Labs	1.4782 of 5 stars	$91.03 -0.6%	$87.14 -4.3%	+104.0%	$2.68B	$211.08M	N/A	1,004	Analyst Forecast
TMDX TransMedics Group	4.2243 of 5 stars	$71.44 +0.3%	$134.50 +88.3%	-34.8%	$2.47B	$605.49M	16.22	210
AXGN AxoGen	3.1005 of 5 stars	$45.65 -0.7%	$46.50 +1.9%	+231.8%	$2.43B	$225.21M	N/A	450	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SIBN) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SiBone (SIBN) Competitors

SIBN vs. WRBY, ESTA, TMDX, AXGN, and LMAT

How does SiBone compare to Warby Parker?

Summary

How does SiBone compare to Establishment Labs?

Summary

How does SiBone compare to TransMedics Group?

Summary

How does SiBone compare to AxoGen?

Summary

How does SiBone compare to LeMaitre Vascular?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SiBone (SIBN) Competitors

SIBN vs. WRBY, ESTA, TMDX, AXGN, and LMAT

How does SiBone compare to Warby Parker?

Does the media refer more to WRBY or SIBN?

Is WRBY or SIBN more profitable?

Do analysts rate WRBY or SIBN?

Do insiders and institutionals believe in WRBY or SIBN?

Which has higher valuation & earnings, WRBY or SIBN?

Which has more volatility and risk, WRBY or SIBN?

Summary

How does SiBone compare to Establishment Labs?

Do insiders & institutionals have more ownership in ESTA or SIBN?

Do analysts recommend ESTA or SIBN?

Which has preferable valuation & earnings, ESTA or SIBN?

Which has more volatility & risk, ESTA or SIBN?

Is ESTA or SIBN more profitable?

Does the media refer more to ESTA or SIBN?

Summary

How does SiBone compare to TransMedics Group?

Do insiders & institutionals hold more shares of TMDX or SIBN?

Which has higher valuation and earnings, TMDX or SIBN?

Do analysts rate TMDX or SIBN?

Is TMDX or SIBN more profitable?

Which has more volatility and risk, TMDX or SIBN?

Does the media refer more to TMDX or SIBN?

Summary

How does SiBone compare to AxoGen?

Do analysts recommend AXGN or SIBN?

Which has more volatility and risk, AXGN or SIBN?

Which has preferable valuation & earnings, AXGN or SIBN?

Is AXGN or SIBN more profitable?

Does the media refer more to AXGN or SIBN?

Do insiders and institutionals have more ownership in AXGN or SIBN?

Summary

How does SiBone compare to LeMaitre Vascular?

Which has more volatility & risk, LMAT or SIBN?

Is LMAT or SIBN more profitable?

Which has preferable valuation & earnings, LMAT or SIBN?

Do analysts recommend LMAT or SIBN?

Do insiders & institutionals have more ownership in LMAT or SIBN?

Does the media favor LMAT or SIBN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN vs. The Competition

SiBone Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools